Neuphoria Therapeutics Inc. NEUP
We are a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine ("ACh") receptor ("a7 receptor") for the acute, "as needed" treatment of social anxiety disorder ("SAD") and for chronic treatment of post-traumatic stress disorder ("PTSD"). There remains a significant unmet medical need for the over 27 million patients in the United States alone suffering from SAD and PTSD. BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, Neuphoria has a strategic partnership with Merck & Co., Inc., known as Merck outside the United States and Canada, with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system ("CNS") conditions. Neuphoria's pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $15.6M | — | — | — |
| R&D | $9.0M | $9.4M | $13.1M | — |
| SG&A | $7.8M | $8.5M | $8.9M | — |
| Total operating expenses | $16.8M | $17.9M | $22.0M | — |
| Operating income | -$1.1M | -$17.9M | -$22.0M | — |
| Pre-tax income | -$838.0K | -$15.6M | -$21.5M | — |
| Income tax | $468.4K | $87.3K | $139.2K | — |
| Net income | -$369.6K | -$15.5M | -$21.4M | — |
| EPS, basic | -0.23 | -18.62 | -0.02 | — |
| EPS, diluted | -0.23 | -18.62 | -0.02 | — |
| Shares, diluted (wtd. avg.) | 1.6M | 832,225 | 1.47B | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $14.2M | $12.6M | $12.2M | $23.2M |
| Receivables | $11.9K | $126.9K | $426.1K | — |
| Total current assets | $15.0M | $13.2M | $13.3M | — |
| Property, plant and equipment | $2.8K | $2.0K | $2.5K | — |
| Goodwill | $8.6M | $8.7M | $8.7M | $8.9M |
| Other intangibles | $4.8M | $5.5M | $6.1M | $0 |
| Total assets | $28.6M | $27.6M | $28.6M | — |
| Accounts payable | $1.2M | $2.2M | $1.4M | — |
| Total current liabilities | $4.2M | $3.8M | $2.7M | — |
| Total liabilities | $9.6M | $10.2M | $6.6M | — |
| Retained earnings | -$178.3M | -$178.0M | -$162.5M | — |
| Total equity | $19.0M | $17.5M | $22.0M | $39.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | $77.2K | -$14.7M | -$14.6M | — |
| Depreciation and amortisation | — | $100.0K | $100.0K | — |
| Stock-based compensation | $163.8K | $814.8K | $1.3M | — |
| Financing cash flow | $1.5M | $15.1M | $3.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-25-223338.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | $15.6M |
| Gross profit | — | — | — | — |
| Net income | — | -$21.4M | -$15.5M | -$369.6K |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Change of control Control of the company has changed hands. Item 5.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |